RGNX - リジェネックスバイオ (REGENXBIO Inc.) リジェネックスバイオ

 RGNXのチャート


 RGNXの企業情報

symbol RGNx
会社名 REGENXBIO Inc (リジェネックスバイオ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 レジェンクスバイオ(REGENXBIO Inc.)は臨床段階のバイオテクノロジー会社である。同社の遺伝子治療製品候補は遺伝子欠損への対処、治療用タンパク質または抗体の生産を可能にするために、遺伝子を細胞に送達するように設計される。同社は代謝性疾患、神経変性疾患及び網膜疾患の治療領域にわたって製品候補を開発する。製品候補であるRGX-314は湿潤加齢性黄斑変性症(湿性AMD)の治療を目的とする。製品候補であるRGX-501はホモ接合性家族性高コレステロール血症(HoFH)の治療を目的とする。同社は2つの重度遺伝的リソソーム蓄積症、ムコ多糖症I型(MPS I)及びムコ多糖症II型(MPS II)の神経学的症状に対処するために、RGX-111とRGX-121等の製品候補を開発する。製品候補は、遺伝子送達プラットフォームであるNAV Technology Platformからウイルスベクターを利用する。   リジェネックスバイオは米国のバイオテクノロジ―企業。主に、組換型アデノウイルス(AAV)遺伝子工学療法の開発、商業化に従事する。AAV遺伝子工学療法では、ウイルス遺伝子はベクタ―を作製、欠損している箇所に治療に有効な遺伝子配列を挿入し、組換型ベクタ―を作製する。同社はAAV7やAAV8など100以上のベクタ―を開発。本社はメリ―ランド州。   REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
本社所在地 9600 Blackwell Road Suite 210 Rockville MD 20850 USA
代表者氏名 Donald J. Hayden ドナルドJ.ヘイデン
代表者役職名 Independent Chairman of the Board
電話番号 +1 240-552-8181
設立年月日 39630
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 139人
url www.regenxbio.com
nasdaq_url https://www.nasdaq.com/symbol/rgnx
adr_tso
EBITDA EBITDA(百万ドル) 73.66900
終値(lastsale) 63.6
時価総額(marketcap) 2054829758.4
時価総額 時価総額(百万ドル) 241.476
売上高 売上高(百万ドル) 175.79800
企業価値(EV) 企業価値(EV)(百万ドル) 1754.982
当期純利益 当期純利益(百万ドル) 78.13000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Regenxbio Inc revenues increased from $7M to $172.4M. Net income totaled $114.8M vs. loss of $36.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Investment Income increase of 36% to $2.1M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.30 to $3.63.

 RGNXのテクニカル分析


 RGNXのニュース

   REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 23rd Annual Meeting  2020/04/28 21:38:00 PR Newswire
ROCKVILLE, Md., April 28, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that three oral…
   Regenxbio (RGNX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release  2020/04/28 16:33:42 Zacks Investment Research
Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Regenxbio EPS misses by $0.32, misses on revenue  2020/02/26 21:13:07 Seeking Alpha
Regenxbio (NASDAQ:RGNX): Q4 GAAP EPS of -$0.72 misses by $0.32. Revenue of $11.77M (-71.1% Y/Y) misses by $27.9M. Press Release
   REGENXBIO Reports Fourth Quarter and Full-Year 2019 Financial Results and Operational Highlights  2020/02/26 21:05:00 PR Newswire
/PRNewswire/ -- Additional data from RGX-314 Phase I/IIa trial for wet AMD expected in 1H 2020 RGX-314 clinical trials for treatment of wet AMD and diabetic…
   REGENXBIO To Host Conference Call on February 26 to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights  2020/02/19 21:05:00 PR Newswire
ROCKVILLE, Md., Feb. 19, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a…
   REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 23rd Annual Meeting  2020/04/28 21:38:00 PR Newswire
ROCKVILLE, Md., April 28, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that three oral…
   Regenxbio (RGNX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release  2020/04/28 16:33:42 Zacks Investment Research
Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Regenxbio EPS misses by $0.32, misses on revenue  2020/02/26 21:13:07 Seeking Alpha
Regenxbio (NASDAQ:RGNX): Q4 GAAP EPS of -$0.72 misses by $0.32. Revenue of $11.77M (-71.1% Y/Y) misses by $27.9M. Press Release
   REGENXBIO Reports Fourth Quarter and Full-Year 2019 Financial Results and Operational Highlights  2020/02/26 21:05:00 PR Newswire
/PRNewswire/ -- Additional data from RGX-314 Phase I/IIa trial for wet AMD expected in 1H 2020 RGX-314 clinical trials for treatment of wet AMD and diabetic…
   REGENXBIO To Host Conference Call on February 26 to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights  2020/02/19 21:05:00 PR Newswire
ROCKVILLE, Md., Feb. 19, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a…
   Regenxbio EPS misses by $0.32, misses on revenue  2020/02/26 21:13:07 Seeking Alpha
Regenxbio (NASDAQ:RGNX): Q4 GAAP EPS of -$0.72 misses by $0.32. Revenue of $11.77M (-71.1% Y/Y) misses by $27.9M. Press Release
   REGENXBIO Reports Fourth Quarter and Full-Year 2019 Financial Results and Operational Highlights  2020/02/26 21:05:00 PR Newswire
/PRNewswire/ -- Additional data from RGX-314 Phase I/IIa trial for wet AMD expected in 1H 2020 RGX-314 clinical trials for treatment of wet AMD and diabetic…
   REGENXBIO To Host Conference Call on February 26 to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights  2020/02/19 21:05:00 PR Newswire
ROCKVILLE, Md., Feb. 19, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a…
   REGENXBIO Announces Presentations at the 16th Annual WORLDSymposium™ 2020  2020/01/29 12:00:00 PR Newswire
ROCKVILLE, Md., Jan. 29, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced several poster…
   REGENXBIO Reports Continued Progress Across Programs in Year-End 2019 Corporate Update  2020/01/09 12:00:00 PR Newswire
ROCKVILLE, Md., Jan. 9, 2020 /PRNewswire/ -- RGX-314 programs for treatment of wet AMD and diabetic retinopathy continue to advance Plans to initiate a pivotal program of subretinal delivery for wet AMD in 2H 2020, following the 12-month assessment of Cohort 5 patients in the Phase I/IIa…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 リジェネックスバイオ RGNX REGENXBIO Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)